Novel observations of earliest precursor stages among notable findings that could help clinicians intervene earlier in patients most likely to progress UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER LINGHUA WANG, M.D., PH.D. CREDIT: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON – A new study by researchers at The University of Texas MD Anderson...
by The Spanish National Cancer Research Centre Credit: Pixabay/CC0 Public Domain Multiple myeloma is a type of cancer that affects plasma cells, the blood cells involved in the production of antibodies. It is the second most common hematologic cancer, accounting for 2% of all cancers of hematologic origin. Multiple myeloma is usually treated with a...
by Rockefeller University Press Compared with a control (left), treatment with a soluble BCMA decoy receptor (right) increases the number of dying cancer cells (brown) in a multiple myeloma tumor growing in mice. Credit: © 2022 Miao et al. Originally published in Journal of Experimental Medicine. 10.1084/jem.20220214 Researchers at Stanford University have developed “decoy receptor” molecules that...
Scripps Research collaborators develop a way to seamlessly create the compound’s complex structure SCRIPPS RESEARCH INSTITUTE CHEMISTS HANS RENATA, PHD, AND ALEXANDER ADIBEKIAN, PHD, BOTH OF SCRIPPS RESEARCH, SAY THE BACTERIAL EXTRACT CEPAFUNGIN I IS IN THE SAME CLASS AS SEVERAL FDA-APPROVED ANTI-CANCER DRUGS, WITH SOME… view more CREDIT: SCRIPPS RESEARCH JUPITER, FL–Scripps Research chemists...
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE A treatment for multiple myeloma that harnesses the body’s cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease. Although more research is needed to determine how well the treatment works, the...
by Institute of Cancer Research Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumors. The drug, called fadraciclib, was jointly discovered by scientists at The Institute of Cancer Research, London, in collaboration with the...
Vitamin D deficiency is associated with reduced overall survival for patients with multiple myeloma (MM), with a differential effect across race, according to a study published online April 21 in Blood Advances. Sarvari V. Yellapragada, M.D., from Michael E. DeBakey VA Medical Center in Houston, and colleagues examined the differential impact of vitamin D deficiency...
by Cancer Research UK A drug has been made available on the NHS in England for adults with a type of blood cancer called multiple myelomawho cannot receive standard treatment. The National Institute for Health and Care Excellence (NICE) recommended the drug, lenalidomide (Revlimid), be offered in combination with the steroid dexamethasone. But only for those who cannot take the current thalidomide-based standard of care or are not able to have...
NEW YORK (GenomeWeb) – Researchers have identified 40 genes that can be disrupted in the early stages of multiple myeloma. While multiple myeloma is characterized by known recurrent chromosomal changes, how the disease first develops isn’t clear. In 2017, there were 30,280 new multiple myeloma cases in the US and 12,590 deaths due to the...
Combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus stem-cell transplantation is associated with longer progression-free survival than RVD alone for adults with multiple myeloma, according to a study published in the April 6 issue of the New England Journal of Medicine. The Study: Michel Attal, M.D., from the Institut Universitaire du Cancer de Toulouse-Oncopole...
